DYNA MOOD

Brand Owner Address Description
DYNAMOOD TRAXON TECHNOLOGIES LTD. Hong Kong Science Park 213 Wireless Ctr,3 Science Park East Ave Shatin Hong Kong DYNA MOOD;Apparatus for lighting, in particular lamps and lights, namely, LED lamps, LED luminaires, and outdoor decorative LED luminaires; Lighting and decorative lighting apparatus and lighting and decorative lighting installations consisting thereof, in particular for exterior parts of buildings, interior parts of buildings, floors, sales areas, stages, industrial installations, and light show installations; parts and fittings for the aforesaid goods; Lighting, decorative lighting and light show apparatus consisting predominantly of a plurality of LED lights, in particular in the form of a strip, net, tube or planar matrix, all for decorative purposes;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.